Masimo (MASI)
(Delayed Data from NSDQ)
$143.49 USD
+3.55 (2.54%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $143.53 +0.04 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$143.49 USD
+3.55 (2.54%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $143.53 +0.04 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Zacks News
Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive
by Zacks Equity Research
Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.
Masimo (MASI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.41% and 2.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
by Zacks Equity Research
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.
Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
by Zacks Equity Research
Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.
Align Technology (ALGN) Beats on Earnings and Revenues in Q3
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.
Will Robust ICL Sales Aid STAAR Surgical (STAA) Q3 Earnings?
by Zacks Equity Research
STAAR Surgical (STAA) is expected to pitch in a solid top-line contribution with its Implantable Collamer Lens (ICL) consisting of the EVO Visian ICL product line.
Will Amedisys' (AMED) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
Amedisys' (AMED) Q3 is anticipated to benefit from a strong uptick across all its three business lines consisting of Home Health, Hospice and Personal Care.
LabCorp (LH) Q3 Earnings Lag Estimates, Guidance Tweaked
by Zacks Equity Research
Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.
Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance
by Zacks Equity Research
Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.
Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.
Masimo (MASI) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?
by Zacks Equity Research
Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.
Will Healthcare Arm Drive BioTelemetry's (BEAT) Q3 Earnings?
by Zacks Equity Research
Product launches, synergies from LifeWatch acquisition and favorable payor mix are expected to have worked in favor of BioTelemetry's (BEAT) Healthcare arm in Q3.
Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.
PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid
by Zacks Equity Research
PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.
What's in Store for Medpace Holdings (MEDP) in Q3 Earnings?
by Zacks Equity Research
Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.